Oncology Xagena
New data from the phase 1b study ( KEYNOTE-001 ) evaluating Pembrolizumab ( MK-3475 ), an investigational anti-PD-1 antibody, as monotherapy in 411 patients with advanced melanoma were presented. Foll ...
A phase 2 multicenter, randomized, open-label, study has evaluated the safety and efficacy of Pidilizumab ( CT-011 ), a humanized anti-PD-1 IgG1k, in patients with metastatic melanoma. Eligibility ...
Ipilimumab ( Yervoy ) is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. A study has assessed the use of Ipilimumab after radiotherapy i ...
The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and ...
The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...
Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were presented during the ESMO ( European Society for Medical Oncology ) 2 ...
Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...
The anti-programmed-death-receptor-1 ( PD-1 ) antibody Pembrolizumab ( Keytruda ) has shown potent antitumour activity at different doses and schedules in patients with melanoma. Researchers have co ...
Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer ( SCLC ), esophageal cancer and o ...
A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ...
Although anti–CTLA-4 and anti–PD-1 monoclonal antibodies ( mAbs ) may overcome T-cell suppression, T-cell activation depends on the engagement of the antigen receptor and the activating costimulation ...
A phase I/II study in patients with metastatic castration-resistant prostate cancer ( mCRPC ) explored Ipilimumab ( Yervoy ) as monotherapy and in combination with radiotherapy, based on the preclinic ...
Cancer radiotherapy ( RT ) may induce what is referred to as the abscopal effect, a regression of non-irradiated metastatic lesions distant from the primary tumor site directly subject to irradiation. ...
Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role of CTLA4 blockade, the impact of chemotherapy on immune cell populations, and the ...
In a phase III trial, Ipilimumab ( Yervoy ) significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Researchers have characterized outcomes of those ...
